131 related articles for article (PubMed ID: 23416308)
21. Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8.
Port A; Shaw JV; Klopp-Schulze L; Bytyqi A; Vetter C; Hussey E; Mammasse N; Ona V; Bachmann A; Strugala D; Reh C; Goteti K
Pharmacol Res Perspect; 2021 Oct; 9(5):e00842. PubMed ID: 34414672
[TBL] [Abstract][Full Text] [Related]
22. First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy Adults.
Shisha T; Posch MG; Lehmann J; Feifel R; Junt T; Hawtin S; Schuemann J; Avrameas A; Danekula R; Misiolek P; Siegel R; Gergely P
Eur J Drug Metab Pharmacokinet; 2023 Sep; 48(5):553-566. PubMed ID: 37532923
[TBL] [Abstract][Full Text] [Related]
23. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Post AB; Redfield RR; Davis GL; Neumann AU; Osborn BL; Freimuth WW; Subramanian GM
Antivir Ther; 2006; 11(1):35-45. PubMed ID: 16518958
[TBL] [Abstract][Full Text] [Related]
24. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
[TBL] [Abstract][Full Text] [Related]
25. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
Lim JJ; Deng R; Derby MA; Larouche R; Horn P; Anderson M; Maia M; Carrier S; Pelletier I; Burgess T; Kulkarni P; Newton E; Tavel JA
Antimicrob Agents Chemother; 2016 Sep; 60(9):5437-44. PubMed ID: 27381392
[TBL] [Abstract][Full Text] [Related]
26. Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study.
Gaggar A; Coeshott C; Apelian D; Rodell T; Armstrong BR; Shen G; Subramanian GM; McHutchison JG
Vaccine; 2014 Sep; 32(39):4925-31. PubMed ID: 25045824
[TBL] [Abstract][Full Text] [Related]
27. Molecular Determinants of GS-9620-Dependent TLR7 Activation.
Rebbapragada I; Birkus G; Perry J; Xing W; Kwon H; Pflanz S
PLoS One; 2016; 11(1):e0146835. PubMed ID: 26784926
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.
Mallalieu NL; Rahimy MH; Crowley CA; Appleman JR; Smith PF; Freddo JL
Clin Ther; 2014 Dec; 36(12):2047-2063.e3. PubMed ID: 25456558
[TBL] [Abstract][Full Text] [Related]
29. Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial.
Ellis AK; Tsitoura DC; Quint D; Powley W; Lee LA
Clin Exp Allergy; 2017 Sep; 47(9):1193-1203. PubMed ID: 28681506
[TBL] [Abstract][Full Text] [Related]
30. Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults.
Gane E; Pastagia M; Schwertschlag U; De Creus A; Schwabe C; Vandenbossche J; Slaets L; Fevery B; Smyej I; Wu LS; Li R; Siddiqui S; Oey A; Musto C; Van Remoortere P
Antivir Ther; 2021 May; 26(3-5):58-68. PubMed ID: 35485332
[TBL] [Abstract][Full Text] [Related]
31. A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults.
Pierson W; Tuefferd M; Herschke F; Slaets L; Crabbe M; Verstappen D; De Pelsmaeker S; Strickland I; Gane EJ; Schwabe C; Zhang Y; Meerts P; Vandenbossche J; Van Remoortere P; Verbrugge I; De Creus A
Antivir Ther; 2023 Jun; 28(3):13596535231172878. PubMed ID: 37199270
[TBL] [Abstract][Full Text] [Related]
32. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
Barbier AJ; Hilhorst M; Van Vliet A; Snyder P; Palfreyman MG; Gawryl M; Dgetluck N; Massaro M; Tiessen R; Timmerman W; Hilt DC
Clin Ther; 2015 Feb; 37(2):311-24. PubMed ID: 25438724
[TBL] [Abstract][Full Text] [Related]
34. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).
Lawitz EJ; Rodriguez-Torres M; Denning J; Mathias A; Mo H; Gao B; Cornpropst MT; Berrey MM; Symonds WT
J Viral Hepat; 2013 Oct; 20(10):699-707. PubMed ID: 24010644
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.
Cass LM; Efthymiopoulos C; Bye A
Clin Pharmacokinet; 1999; 36 Suppl 1():1-11. PubMed ID: 10429835
[TBL] [Abstract][Full Text] [Related]
36. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy.
Lawitz E; Godofsky E; Rouzier R; Marbury T; Nguyen T; Ke J; Huang M; Praestgaard J; Serra D; Evans TG
Antiviral Res; 2011 Mar; 89(3):238-45. PubMed ID: 21255610
[TBL] [Abstract][Full Text] [Related]
37. Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines.
Klauber TCB; Laursen JM; Zucker D; Brix S; Jensen SS; Andresen TL
Acta Biomater; 2017 Apr; 53():367-377. PubMed ID: 28153581
[TBL] [Abstract][Full Text] [Related]
38. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Gane EJ; Roberts SK; Stedman CA; Angus PW; Ritchie B; Elston R; Ipe D; Morcos PN; Baher L; Najera I; Chu T; Lopatin U; Berrey MM; Bradford W; Laughlin M; Shulman NS; Smith PF
Lancet; 2010 Oct; 376(9751):1467-75. PubMed ID: 20951424
[TBL] [Abstract][Full Text] [Related]
39. Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement.
Tsitoura D; Ambery C; Price M; Powley W; Garthside S; Biggadike K; Quint D
Clin Pharmacol Ther; 2015 Oct; 98(4):369-80. PubMed ID: 26044169
[TBL] [Abstract][Full Text] [Related]
40. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
